Sidoti Csr Predicts Kamada’s Q1 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Stock analysts at Sidoti Csr lifted their Q1 2026 earnings per share (EPS) estimates for shares of Kamada in a research report issued to clients and investors on Tuesday, December 9th. Sidoti Csr analyst J. Sidoti now expects that the biotechnology company will post earnings of $0.09 per share for the quarter, up from their previous forecast of $0.07. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. Sidoti Csr also issued estimates for Kamada’s Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.11 EPS, FY2026 earnings at $0.41 EPS, Q1 2027 earnings at $0.10 EPS, Q2 2027 earnings at $0.12 EPS, Q3 2027 earnings at $0.14 EPS and FY2027 earnings at $0.49 EPS.

Kamada (NASDAQ:KMDA) last released its earnings results on Monday, November 10th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Kamada had a net margin of 11.70% and a return on equity of 7.89%. The company had revenue of $47.01 million during the quarter, compared to analysts’ expectations of $154.21 million.

Other equities research analysts have also issued reports about the company. HC Wainwright upped their price target on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen cut Kamada from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

Kamada Trading Up 1.2%

Shares of KMDA opened at $6.81 on Wednesday. Kamada has a twelve month low of $5.54 and a twelve month high of $9.15. The firm has a market capitalization of $391.64 million, a P/E ratio of 18.92, a price-to-earnings-growth ratio of 0.72 and a beta of 0.92. The stock’s fifty day simple moving average is $6.86 and its 200 day simple moving average is $7.10.

Institutional Investors Weigh In On Kamada

A number of large investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC increased its position in shares of Kamada by 4.2% during the third quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock worth $366,000 after acquiring an additional 2,125 shares during the last quarter. ARK Investment Management LLC boosted its stake in Kamada by 1.2% during the 3rd quarter. ARK Investment Management LLC now owns 256,217 shares of the biotechnology company’s stock valued at $1,779,000 after acquiring an additional 2,943 shares during the last quarter. Two Sigma Investments LP boosted its stake in Kamada by 4.3% during the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after acquiring an additional 4,504 shares during the last quarter. Huntleigh Advisors Inc. increased its position in shares of Kamada by 3.9% in the 2nd quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company’s stock worth $1,052,000 after purchasing an additional 5,151 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Kamada by 3.1% in the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock worth $2,053,000 after purchasing an additional 7,925 shares during the last quarter. 20.38% of the stock is owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.